Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $71.50 short put and a strike $66.50 long put offers a potential 8.7% return on risk over the next 11 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $71.50 by expiration. The full premium credit of $0.40 would be kept by the premium seller. The risk of $4.60 would be incurred if the stock dropped below the $66.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 72.81 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly, Incyte Arthritis Drug Meets Endpoint
Tue, 09 Dec 2014 13:17:36 GMT
Rethinking The Role Of The Corporation — From Philanthropy To Shared Value
Tue, 09 Dec 2014 13:00:00 GMT
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
Tue, 09 Dec 2014 12:20:03 GMT
noodls – FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS Dec 9, 2014 7:00am INDIANAPOLIS , Dec. 9, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that …
7:06 am Eli Lilly and Incyte (INCY) announced positive top-line results from Phase 3 Trial of Baricitinib in moderate to severe rheumatoid arthritis; met its primary endpoint
Tue, 09 Dec 2014 12:06:00 GMT
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
Tue, 09 Dec 2014 12:05:35 GMT
noodls – INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib …
Related Posts
Also on Market Tamer…
Follow Us on Facebook